Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.54, compared with -$0.49 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.42.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$1.38 (+0.2%) for the fiscal year ending Dec 2026, a slowdown from the +16.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.54-437.5% QoQ
- Last fiscal yearDec 2025
- -$1.38+16.9% YoY
- LTMMar 2026
- -$1.42+19.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.2% | +21.6% | +31.8 pp |
| 1 year | +16.9% | +0.2% | -16.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.38) USD
- Year-over-year change
- +16.9%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.38) | +16.9% |
| FY2024 | 2024-12-31 | (1.66) | -12.2% |
| FY2023 | 2023-12-31 | (1.48) | -12.1% |
| FY2022 | 2022-12-31 | (1.32) | -7035.1% |
| FY2021 | 2021-12-31 | (0.02) | — |
EPS (Diluted) vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +19.8% is the 6th highest of 11, against a peer median of +26.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.37 USD | +68.8% | — | |
| LTM Mar 2026 | -$0.47 USD | +59.5% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$1 USD | -29.9% | — |
| LTM Mar 2026 | -$1.06 USD | +37.3% | — | |
| LTM Mar 2026 | -$1.31 USD | +16.6% | — | |
| LTM Mar 2026 | -$1.42 USD | +19.8% | — | |
| LTM Mar 2026 | -$1.42 USD | +12.3% | — | |
| LTM Mar 2026 | -$1.46 USD | +15.1% | — | |
| FY2025 | -€1.82 EUR | +48.6% | — | |
| LTM Mar 2026 | -$2.74 USD | +39.6% | — | |
| LTM Mar 2026 | -$5.83 USD | -124.1% | — | |
| Peer median (excluding OBIO) | — | +26.9% | — | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | (782K) | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | 199K | 322K | 186K | 204K | 190K |
| Gross Profit | (981K) | 3.21M | 2.57M | 2.43M | 33.29M |
| Gross Margin | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| Research & Development | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| Selling, General & Admin | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| Operating Expenses | 20.82M | 35.87M | 54.08M | 66.74M | 85.1M |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| EBITDA | (21.91M) | (33.39M) | (48.83M) | (60.72M) | (51.23M) |
| EBITDA Margin | 2801.3% | -945.0% | -1769.3% | -2301.6% | -153.0% |
| Operating Income | (21.8M) | (32.66M) | (51.51M) | (64.3M) | (51.81M) |
| Operating Margin | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Interest Income | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 927K | 0 | 0 | 0 | 1.15M |
| Other Income / Expenses | (1.22M) | (951K) | 2.39M | 3.28M | (894K) |
| Income Before Tax | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Pre-Tax Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Net Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (Basic) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| EPS (Diluted) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| Weighted Avg Shares | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
| Weighted Avg Shares (Diluted) | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.